Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Valentina FanottoDaniele RossiniMariaelena CasagrandeFrancesca BergamoAndrea SpagnolettiDaniele SantiniCarlotta AntoniottiSamanta CupiniFrancesca DanielVincenzo NascaGuglielmo VetereAlberto ZaniboniBeatrice BorelliMartina CarulloVeronica ConcaAlessandro PassardiEmiliano TamburiniGianluca MasiNicoletta PellaChiara CremoliniPublished in: Cancers (2023)
PTR at baseline was independently associated with good prognosis in synchronous mCRC patients and with lower incidence of serious gastrointestinal and surgical AEs during upfront chemotherapy plus bevacizumab. The benefit and toxicity profile of FOLFOXIRI plus bevacizumab was independent of PTR.